Categories: aggregated

Patient Zero for Untreatable Depression Begins Groundbreaking Psychedelics Therapy – Ending Depression Through Psilocybin?

In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.

Jason

Share
Published by
Jason

Recent Posts

Medical Cannabis in 2026: What 500+ Studies Proved for Pain, Dementia & Sleep

The heavyweight is a network meta-analysis of 28 randomized controlled trials covering 3,058 adults, which…

10 hours ago

Will Texas Legalize Weed in 2027? What the Blue Wave Means for Cannabis in the Lone Star State

So, will Texas legalize? Maybe not in 2027. But the people who blocked it are…

2 days ago

AI Data Centers Are Taking Over Cannabis Farms—And Why You Might Need to Grow Your Own Weed

Struggling cannabis farms are eyeing a second life as data centers. The grow room you…

3 days ago

A Beginner’s Guide to Low-Dose Social Drinking

Low-dose THC beverages typically contain somewhere between 2 and 5 mg of THC per serving.…

6 days ago

6 Surprising Truths Cannabis Actually Teaches You About Yourself

A few dozen strangers answered one question, and here's what they told me. Cannabis rarely…

1 week ago

DEA Hearing Bombshell: Marijuana Rescheduling Rules Never Existed

Federal officials admitted under oath at the DEA marijuana rescheduling hearing that the 54-year-old test…

1 week ago